This is a working overview of gastric juice protein, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-20 and is reviewed periodically as new material appears.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
In 1885 Eddy was accused of promoting Spiritualism and pantheism by the Reverend Adoniram J. Gordon, in a letter read out by Joseph Cook during one of his popular Monday lectures at Tremont Temple in Boston. She demanded a right of reply, and on March 16, 1885, she told the congregation that she was not a Spiritualist, and that she believed in God as the Supreme Being and in the atonement. She described Christian Science healing as "Christ come to destroy the power of the flesh." Stephen Gottschalk wrote that the occasion marked the "emergence of Christian Science into American religious life." The first church building was erected in 1886 in Oconto, Wisconsin, by local women who believed Christian Science had helped them. For a down payment of $2,000 and a mortgage of $8,763, the church purchased land in Falmouth Street, Boston, for the erection of a building. Eddy asked Augusta Stetson, a prominent Scientist, to establish a church in New York. By the end of 1886 Christian Science teaching institutes had sprung up around the United States. In December 1887 Eddy moved to a $40,000, 20-room house at 385 Commonwealth Avenue, Boston. She had been teaching four to six classes a year, and by 1889 had probably made at least $100,000 (equivalent to $3,583,000 in 2025). By 1890 the Church of Christ (Scientist) had 8,724 members in the United States, having started 11 years earlier with just 26.
=== Other family members === Audrey Conner (Ann Wedgeworth and Debbie Reynolds) – She is the mother of Dan Conner, and the ex-wife of Ed Conner. In Season 2 she is introduced in "We Gather Together" as a friendly, eccentric brunette woman who loves her son and her new boyfriend, as well as her successful career owning a travel agency. It's later revealed that she has a history of mental illness which Dan's father hid from him. She returns in person in season 9, angry at her son for putting her away, seemingly trying to kill him. Her nurse at the mental institution is who Dan had a relationship with while being married to Roseanne. Note, however, that as almost all of season 9 was retconned out of existence, this no longer can be assumed to be 'true' within the show's continuity. (Initially, Dan's affair was revealed to be false, and part of a story Roseanne was writing as a way to deal with Dan's heart-attack death in the previous season. By season 10, even Dan's death was retconned away.) Al Harris (John Randolph) – Al is portrayed as Roseanne and Jackie's henpecked yet humorous father with a knack for telling knock-knock jokes. Al initially appears to have a good relationship with his daughters, especially Jackie, and despite having more in common with her mother, Roseanne finds her father more bearable to be around. Randolph made two appearances as Al Harris during the show's first two seasons. In season four, however, his character changes dramatically. After being unable to secure Randolph for future shows, Al was written out of the series.
In peptoids, the side chain is connected to the nitrogen of the peptide backbone, instead of the α-carbon as in peptides. Notably, peptoids lack the amide hydrogen which is responsible for many of the secondary structure elements in peptides and proteins. Peptoids were first invented by Reyna J. Simon, Ronald N. Zuckermann, Paul Bartlett and Daniel V. Santi to mimic protein/peptide products to aid in the discovery of protease-stable small molecule drugs for the East Bay company Chiron. Following the sub-monomer protocol originally created by Ron Zuckermann, each residue is installed in two steps: acylation and displacement. In the acylation step, a haloacetic acid, typically bromoacetic acid activated by diisopropylcarbodiimide reacts with the amine of the previous residue. In the displacement step (a classical SN2 reaction), an amine displaces the halide to form the N-substituted glycine residue. The submonomer approach allows the use of any commercially available or synthetically accessible amine with great potential for combinatorial chemistry.
Sources: en.wikipedia.org
which can be understood as converting kinetic energy to work, was largely the result of Gaspard-Gustave Coriolis and Jean-Victor Poncelet over the period 1819–1839. The former called the quantity quantité de travail (quantity of work) and the latter, travail mécanique (mechanical work), and both championed its use in engineering calculations. In the paper Über die Natur der Wärme (German "On the Nature of Heat/Warmth"), published in the Zeitschrift für Physik in 1837, Karl Friedrich Mohr gave one of the earliest general statements of the doctrine of the conservation of energy: "besides the 54 known chemical elements there is in the physical world one agent only, and this is called Kraft [energy or work]. It may appear, according to circumstances, as motion, chemical affinity, cohesion, electricity, light and magnetism; and from any one of these forms it can be transformed into any of the others."
=== Monoclonal anti-asprosin antibody === Mishra and colleagues have demonstrated that anti-asprosin mAbs (monoclonal antibody) are a dual-effect therapy that targets the two key pillars of metabolic syndrome – overnutrition and plasma glucose burden. Specifically, anti-asprosin mAbs have been shown to reduce blood glucose, appetite, and body weight in various diet-induced and genetic models of metabolic syndrome. These findings have led to an effort to optimize and develop clinical-grade anti-asprosin mAbs for use in humans. Asprosin has also been reported to cross the blood–brain barrier to regulate neurons in the hypothalamus of the brain known to regulate hunger and satiety, and inhibiting asprosin in obese mice reduced feeding and led to decreased body weight.
has continued to assist the Mexican government with technology, equipment, training and intelligence. However, critics argue that gun politics in the United States have exacerbated the conflict by enabling the flow of weapons south of the border.
Sources: en.wikipedia.org
=== In the media === Media coverage has largely focused on law-enforcement solutions to the epidemic, which portray the issue as criminal, whereas some see it as a medical issue. There has been differential reporting on how white suburban or rural addicts of opioids are portrayed compared to black and Hispanic urban addicts, often of heroin, reinforcing stereotypes of drug users and drug-using offenders. In newspapers, white addicts' stories are often given more space, allowing for a longer backstory explaining how they became addicted, and what potential they had before using drugs. In early 2016 the national desk of The Washington Post began an investigation with assistance from fired Drug Enforcement Administration regulator Joseph Razzazzisi on the rapidly increasing numbers of opioid related deaths. While media coverage has focused more heavily on overdoses among whites, use among African, Hispanic and Native Americans has increased at similar rates. Deaths by overdose among white, black, and Native Americans increased by 200–300% from 2010 to 2014. During this time period, overdoses among Hispanics increased 140%, and the data available on overdoses by Asians was not comprehensive enough to draw a conclusion. In August 2014, the website Annals of Emergency Medicine collaborated with the Academic Life in Emergency Medicine (ALiEM) and posted a discussion board about the opioid epidemic. The discussion acquired a little over 1000 readers and lasted roughly 14 days.
Agaricales (including now-obsolete orders Lycoperdales, Tulostomatales, and Nidulariales) Basidiomycetes: Agaricales: Lycoperdaceae: Calvatia Calvatia booniana Calvatia bovista (Handkea utriformis) Calvatia craniiformis Calvatia cyathiformis Calvatia fumosa (Handkea fumosa) Calvatia gigantea Calvatia lepidophora Calvatia rubroflava Calvatia sculpta Calvatia subcretacea (Handkea subcretacea) Basidiomycetes: Agaricales: Lycoperdaceae: Lycoperdon Lycoperdon foetidum (Lycoperdon nigrescens) Lycoperdon perlatum Lycoperdon pulcherrimum Lycoperdon pusillum Lycoperdon pyriforme Basidiomycetes: Agaricales: Lycoperdaceae: Vascellum Vascellum curtisii Vascellum pratense – edible when interior is white Geastrales and Phallales (related to Cantharellales), Basidiomycetes: Phallales: Geastraceae: Geastrum Geastrum coronatum Geastrum fornicatum Geastrum saccatum Sclerodermatales (related to Boletales) Basidiomycetes: Boletales: Sclerodermataceae: Scleroderma Scleroderma areolatum Scleroderma bovista Scleroderma cepa Scleroderma citrinum Scleroderma meridionale Scleroderma michiganense Scleroderma polyrhizum Scleroderma septentrionale Various false-truffles (hypogaeic gasteromycetes) related to different hymenomycete orders Similarly, the true truffles (Tuberales) are gasteroid Ascomycota. Their ascocarps are called tuberothecia.
The following table is based on the ISSCAAP classification (International Standard Statistical Classification of Aquatic Animals and Plants) used by the FAO to collect and compile fishery statistics. The production figures have been extracted from the FAO FishStat database, and include both capture from wild fisheries and aquaculture production.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.